NUDCD2

Across TCGA pan-cancer cohorts, NUDCD2 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of NUDCD2’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where NUDCD2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types NUDCD2 is over-expressed in tumor, although a few such as LSCC and HNSC show the opposite, repressed pattern.

LSCC, HNSC, and COAD are the cancer types where NUDCD2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in NUDCD2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Female	All	−0.406	<.001	9	view →
HNSC	Male	All	−0.266	<.001	8	view →
COAD	Female	All	−0.146	<.001	8	view →
PDAC	Female	All	−0.273	.007	6	view →
CCRCC	Male	All	+0.130	<.001	6	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

NUDCD2–LSCC

Open the LSCC breakdown →